{"id":6846,"date":"2026-05-21T14:37:27","date_gmt":"2026-05-21T12:37:27","guid":{"rendered":"https:\/\/www.institut-biotherapies.fr\/?p=6846"},"modified":"2026-05-26T09:39:37","modified_gmt":"2026-05-26T07:39:37","slug":"genethon-and-ampersand-biomedicines-announce-partnership-to-design-novel-aav-vectors-with-enhanced-tissue-specificity-for-more-effective-and-better-tolerated-gene-therapies","status":"publish","type":"post","link":"https:\/\/www.institut-biotherapies.fr\/en\/2026\/05\/21\/genethon-and-ampersand-biomedicines-announce-partnership-to-design-novel-aav-vectors-with-enhanced-tissue-specificity-for-more-effective-and-better-tolerated-gene-therapies\/","title":{"rendered":"Genethon and Ampersand Biomedicines announce partnership to design novel AAV vectors with enhanced tissue specificity for more effective and better tolerated gene therapies"},"content":{"rendered":"<p><strong>Genethon, the French pioneer in the discovery and development of gene therapies for rare diseases, and Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, announce an exclusive collaboration to engineer a new generation of AAV capsids with superior tissue specificity. This strategic partnership brings together two highly complementary R&amp;D teams with synergistic scientific capabilities, aiming to unlock the full therapeutic potential of AAV-based gene therapy.<\/strong><\/p>\n<p><a href=\"https:\/\/www.genethon.com\/genethon-and-ampersand-biomedicines-announce-partnership-to-design-novel-aav-vectors-with-enhanced-tissue-specificity-for-more-effective-and-better-tolerated-gene-therapies\/\">Read more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Genethon, the French pioneer in the discovery and development of gene therapies for rare diseases, and Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, announce an exclusive collaboration to engineer a new generation of AAV capsids with superior tissue specificity. This &hellip; <a href=\"https:\/\/www.institut-biotherapies.fr\/en\/2026\/05\/21\/genethon-and-ampersand-biomedicines-announce-partnership-to-design-novel-aav-vectors-with-enhanced-tissue-specificity-for-more-effective-and-better-tolerated-gene-therapies\/\">[Read more]<\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-6846","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/6846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/comments?post=6846"}],"version-history":[{"count":1,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/6846\/revisions"}],"predecessor-version":[{"id":6847,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/6846\/revisions\/6847"}],"wp:attachment":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/media?parent=6846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/categories?post=6846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/tags?post=6846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}